ArticleSurgery today2026
Histological treatment response to neoadjuvant chemotherapy predicts the survival outcomes of patients with resectable pancreatic cancer: validation of the Japan Pancreas Society grading system.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo validate the prognostic value of histological treatment response, assessed using the Japan Pancreas Society (JPS) grading system, in patients with resectable pancreatic ductal adenocarcinoma (PDAC) treated with neoadjuvant chemotherapy (NAC) followed by surgical resection.
methodsWe analyzed, retrospectively, data from 117 consecutive patients who underwent NAC and curative-intent PDAC resection at Tohoku University Hospital between January 2010 and December 2022. Histological responses were graded using the JPS system. Survival analyses were conducted using Kaplan-Meier estimation and Cox proportional hazards modeling.
resultsHistological Grade 1a, 1b, 2, 3, and 4 responses were observed in 47 (40.2%), 42 (35.9%), 21 (17.9%), 6 (5.1%), and 1 (0.9%) patients, respectively. Patients with a Grade ≥ 2 response had significantly longer overall survival (OS) and significantly higher R0 resection rates than those with Grade 1a or 1b responses (median OS: 118.7 vs. 46.6 months, p = 0.037; 100% vs. 82.0%, p = 0.01). In a multivariable Cox regression model including RECIST progression status and baseline covariates, JPS Grade ≥ 2 remained significantly associated with better OS (adjusted HR 0.48; 95% CI 0.24-0.96; p = 0.039).
conclusionSubstantial histological response (JPS Grade ≥ 2) after NAC is strongly associated with improved OS and higher R0 resection rates in patients with resectable PDAC. The JPS grading system provides a basis for clinically meaningful prognostic stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.